Royal College of Surgeons in Ireland
Design and rationale of a randomized trial of COBRA PzF stenting to....pdf (616.17 kB)

Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE)

Download (616.17 kB)
Version 2 2023-10-10, 14:52
Version 1 2021-05-27, 12:40
journal contribution
posted on 2021-05-27, 12:40 authored by Roisin ColleranRoisin Colleran, Michael Joner, Donald Cutlip, Philip Urban, Michael Maeng, Rajiv Jauhar, Mark Barakat, Jonathan M Michel, Roxana Mehran, Ajay J Kirtane, Luc Maillard, Adnan Kastrati, Robert ByrneRobert Byrne, COBRA-REDUCE investigators

Background/purpose: A coronary stent with thromboresistant and pro-healing properties such as the polymer polyzene F-coated (COBRA PzF) stent might safely allow for a very short duration of triple therapy in patients taking oral anticoagulation (OAC) who undergo coronary stenting.

Methods: The COBRA-REDUCE trial is a prospective, multinational, randomized, open-label, assessor-blinded trial. A total of 996 patients at high bleeding risk because of requirement for OAC (with a vitamin K antagonist or non-vitamin K antagonist for any indication) will be randomized at sites in the United States and Europe to treatment with the COBRA-PzF stent followed by very short duration (14 days) DAPT or a Food and Drug Administration (FDA)-approved new generation drug-eluting stent followed by guideline-recommended DAPT duration (3 or 6 months). Two co-primary endpoints will be tested at 6 months: a bleeding co-primary endpoint (bleeding academic research consortium [BARC] ≥2 bleeding beyond 14 days or after hospital discharge, whichever is later [superiority hypothesis]) and a thrombo-embolic co-primary endpoint (the composite of all-cause death, myocardial infarction, definite/probable stent thrombosis or ischaemic stroke [non-inferiority hypothesis]). The trial is registered at (NCT02594501).

Conclusion: The COBRA-REDUCE trial will determine whether coronary stenting with the COBRA PzF stent followed by 14 days of clopidogrel will reduce bleeding without increasing thrombo-embolic events compared with FDA-approved DES followed by 3-6 months clopidogrel in patients taking OAC and aspirin.


CeloNova BioSciences Inc. San Antonio, TX, USA



The original article is available at

Published Citation

Colleran R, Joner M, Cutlip D, Urban P, Maeng M, Jauhar R, Barakat M, Michel JM, Mehran R, Kirtane AJ, Maillard L, Kastrati A, Byrne RA, COBRA-REDUCE investigators. Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE). Cardiovasc Revasc Med. 2021:S1553-8389(21)00051-8.

Publication Date

22 January 2021

PubMed ID



  • School of Pharmacy and Biomolecular Sciences

Research Area

  • Vascular Biology




  • Published Version (Version of Record)